I agree that this site is using cookies. You can find further informations here.
X
Hodi, F. Stephen
319  results:
OpenAccess-fulltext X
Search for persons X
?
1

Defining the Critical Hurdles in Cancer Immunotherapy:

Fox, B.A. (Bernard A.) ; Schendel, D. J. (Dolores J.) ; Butterfield, L.H. (Lisa H.)...
http://www.translational-medicine.com/content/9/1/214/abstract.  , 2011
Link: https://hdl.handle.net/1..
 
?
2

EDIL3 as an Angiogenic Target of Immune Exclusion Following..:

Tabasum, Saba ; Thapa, Dinesh ; Giobbie-Hurder, Anita...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618652/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
3

Combination of Itacitinib or Parsaclisib with Pembrolizumab..:

Munster, Pamela ; Iannotti, Nicholas ; Cho, Daniel C...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10729644/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
4

First-in-human phase I study of the OX40 agonist GSK3174998..:

Postel-Vinay, Sophie ; Lam, Vincent K ; Ros, Willeke...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10030671/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
5

Liquid biopsy epigenomic profiling for cancer subtyping:

Baca, Sylvan C ; Seo, Ji-Heui ; Davidsohn, Matthew P...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10695830/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
6

Granulocyte–Macrophage Colony-Stimulating Factor Influence ..:

Li, Xiaoyu ; Li, Jingjing ; Zheng, Yue...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398357/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
7

Brief Communication on Pathologic Assessment of Persistent ..:

Buchbinder, Elizabeth I ; Pfaff, Kathleen L ; Turner, Madison M...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10168111/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
8

Infliximab for Steroid-Refractory Immune Checkpoint Inhibit..:

Townsend, Matthew J ; Hodi, F. Stephen ; Grover, Shilpa
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043592/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
9

Patient-reported Tolerability of Adjuvant Ipilimumab (3 or ..:

McLouth, Laurie E ; Zheng, Yue ; Smith, Stephanie...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9839512/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
10

Mass cytometry staining for human bone marrow clinical samp..:

Hallisey, Margaret ; Dennis, Jenna ; Abrecht, Charlotte...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8861824/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
11

First-In-Human Phase I Study of the OX40 Agonist MOXR0916 i..:

Kim, Tae Won ; Burris, Howard A ; de Miguel Luken, Maria J...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662912/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
12

Durvalumab, tremelimumab alone or in combination with low-d..:

Schoenfeld, Jonathan D ; Giobbie-Hurder, Anita ; Ranasinghe, Srinika...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8813905/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
13

Mechanical checkpoint regulates monocyte differentiation in..:

Vining, Kyle H ; Marneth, Anna E ; Adu-Berchie, Kwasi...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10197159/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
14

Chemotherapy Dose Shapes the Expression of Immune-Interacti..:

Najibi, Alexander J ; Larkin, Kerry ; Feng, Zhaoqianqi...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751245/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
15

Improved prognosis and evidence of enhanced immunogenicity ..:

Tarhini, Ahmad A ; Lee, Sandra J ; Tan, Aik-Choon...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8788316/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
1-15